败血症期间人体免疫细胞子集中反应性氧物种的升高被诺拉皮内和N-乙半氨酸减轻
Joby Thoppil1, J David Farrar2, Drashya Sharma2
1Department of Emergency Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390, United States. joby.thoppil@utsouthwestern.edu.
World journal of critical care medicine
|December 11, 2025
概括
败血症会提高T细胞和单细胞中的活性氧物种 (ROS). 上腺素 (NE) 和N-乙半氨酸 (NAC) 在体外降低了这些ROS水平,这表明在败血症期间在免疫氧化还原调节中发挥了作用.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 败血症涉及到对感染的失调宿主反应,可能导致免疫细胞的氧化还原失衡.
- 反应性氧物种 (ROS) 在免疫细胞信号传递中发挥作用,它们的过量可以改变败血症中的免疫功能.
研究的目的:
- 测量从败血症患者的外周血液单核细胞 (PBMC) 子集中的细胞内ROS.
- 为了研究在炎症刺激后PBMCs中N-上腺素 (NE) 和N-乙半氨酸 (NAC) 对ROS水平的体外影响.
主要方法:
- 从败血症患者和健康对照者中分离了周围血液单核细胞 (PBMC).
- 细胞内ROS水平使用流动细胞计测量.
- 在实验室中,用脂多糖 (LPS) 或过氧化 (H2O2) 刺激PBMC,然后用NE或NAC进行治疗.
主要成果:
- 与对照人群相比,ROS水平在败血症患者的CD3+ T细胞和CD14+单细胞中显著更高.
- 试验室刺激增加了对照PBMC中的ROS,这种效应被NE和NAC联合治疗减弱.
结论:
- 在特定的PBMC亚组 (CD3+ T细胞,CD14+单细胞) 中ROS升高是败血症的特征.
- 通过减少ROS积累,NE和NAC在体外显示出作为氧化还原调节剂的潜力.
- 需要进一步的研究来探索毒症中免疫氧化还原调节的机制.
相关概念视频
Acute Kidney Injury II: Pathophysiology
854
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
854
Acute Respiratory Failure-V
421
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
421


